At the recent Asia Pacific Alliance for the Control of Influenza (APACI) workshop in Kuala Lumpur, MIMS Doctor had the privilege of having an exclusive interview with eminent paediatric infectious disease specialist, Associate Professor Tawee Chotpitayasunondh. This article captures the highlights from our conversation with him.
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
The Asia Pacific Alliance for the Control of Influenza (APACI) recently organized an influenza workshop in Kuala Lumpur. The workshop saw eminent speakers from seven countries presenting on topics concerning the impact of influenza, vaccination of various populations, current and upcoming treatments for influenza, policy considerations and approaches for pandemic preparedness. Read about highlights from the workshop in this newsletter.
At the recent Infectious Disease Symposium held on the 5th of August 2016, at Le Meridien Kuala Lumpur, two speakers spoke on the role of macrolides in the management of respiratory tract infections, as well as the importance of antibiotic stewardship in combating microbial resistance.
Antimicrobial resistance is an increasingly serious threat to global public health. To address this, Associate Professor de Castro recently sat down with MIMS Doctor to give her views on the judicious use of antimicrobial agents.
The Malaysian Paediatric Association's 37th Annual Congress and the Asia Pacific Vaccinology Update saw two eminent speakers discussing the rationale for vaccination against rotavirus and Streptococcus pneumoniae infections in children.
Use of systemic antibiotics, in conjunction with performance of incision and drainage, in the management of paediatric acute skin and soft tissue infection (SSTI) appears to reduce Staphylococcus aureus colonization and the likelihood of infection recurrence, a prospective study has found.
Retreatment with ledipasvir and sofosbuvir with add-on ribavirin appears to be effective and well tolerated in genotype 1 hepatitis C virus (HCV)-infected patients who have failed to respond to daclatasvir/asunaprevir combination therapy, according to a study.